|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's Range||16.81 - 17.35|
|52 Week Range||15.18 - 30.34|
|Beta (3Y Monthly)||1.47|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.00|
Theravance's (TBPH) newly-launched COPD drug Yupelri is witnessing a solid adoption while its pipeline programs are also progressing well. However, excessive reliance on Yupelri for revenues is a woe.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
DUBLIN , Sept. 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on ...
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.
DUBLIN, Sept. 9, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced initial results, including positive biomarker responses, from its Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial of TD-8236, an investigational, lung-selective inhaled pan-Janus kinase (JAK) inhibitor for inflammatory lung diseases. TD-8236 is specifically designed to be delivered to the lung via dry powder inhalation, targeting airway inflammation in the lung with minimal systemic exposure.
DUBLIN , Aug. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in fireside chats at two upcoming investor conferences: 14 th ...
Anyone researching Theravance Biopharma, Inc. (NASDAQ:TBPH) might want to consider the historical volatility of the...
Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.
Theravance Bio (TBPH) delivered earnings and revenue surprises of 40.98% and 87.91%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Late-stage clinical studies of TD-1473 and ampreloxetine progressing - Phase 1 results including biomarker data in asthmatics for lung-selective inhaled pan-JAK inhibitor TD-8236 expected in September ...
DUBLIN, July 22, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today reported new data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) in patients with neurogenic orthostatic hypotension (nOH) in an oral presentation at the 32nd European Neurology Congress. New data demonstrated that patients experienced improvements in their overall nOH symptoms and in their ability to perform daily activities following four weeks of treatment, and that these improvements were sustained until the completion of 20 weeks of ampreloxetine therapy.
Rick Winningham has been the CEO of Theravance Biopharma, Inc. (NASDAQ:TBPH) since 2014. This report will, first...
AstraZeneca (AZN) gets approval in Japan for PT010, its triple-combo inhaler and Bevespi Aerosphere, a fixed-dose LABA/LAMA inhaler, both to treat COPD.